Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Denatured type I collagen refers to the unwound or proteolytically degraded state of the most abundant structural protein in the human extracellular matrix (ECM). While native type I collagen forms a stable triple helix that provides mechanical strength to tissues like skin, bone, and tendons, denaturation occurs during pathological remodeling driven by matrix metalloproteinases (MMPs) or mechanical stress (Hwang et al., 2017, ACS Nano). This structural transition exposes cryptic epitopes—binding sites that are hidden in the native protein—which play critical roles in cell signaling, particularly through interactions with integrins like alpha-v-beta-3 (Xu et al., 2001, J. Cell Biol.). In diseases such as cancer and fibrosis, denatured collagen is a hallmark of the remodeled microenvironment, promoting angiogenesis and tumor invasion (Brooks et al., 1998, Cell). Consequently, it serves as a highly selective target for diagnostic imaging and site-specific drug delivery, using agents like collagen-hybridizing peptides (CHPs) or monoclonal antibodies that distinguish between healthy native tissue and diseased, remodeling tissue (Li & Yu, 2013, Soft Matter). These targeting strategies aim to deliver therapeutic payloads or block the pro-migratory signals provided by the degraded matrix (Bennink et al., 2018, Sci Rep).
Selective binding to exposed cryptic epitopes in denatured collagen to inhibit angiogenesis, block cell-matrix interactions, or deliver therapeutic payloads to remodeling tissues.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Denatured type I collagen.